Protocol Ledger

NCT06711900 · Phase III · ACTIVE NOT RECRUITING

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cel

Interventional Phase III clinical trial protocol NCT06711900 sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-30 Enrollment: 432 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06711900
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)432 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06711900
Protocol FieldVerified Registry Value
NCT IdentifierNCT06711900
Consolidated Lead SponsorSichuan Kelun-Biotech Biopharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment432 participants (ESTIMATED)
Registered Start Date2024-10-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI